Improving Cardiovascular Outcomes in T2DM: Personalizing Antihyperglycemic Therapy

Approximately 13% of the US adult population has diabetes, with the majority (95%) having type 2 diabetes mellitus (T2DM). Cardiovascular disease (CVD) is the number one cause of death for patients with T2DM. The pathophysiology of T2DM contributes to atherogenesis and has a direct effect on the myocardium.

The cardiovascular effects of newer antihyperglycemic drugs have been studied in prospective cardiovascular outcomes trials, while information from older agents comes from observational studies and meta-analyses. These data led many societies to publish updated guidelines on the management of patients with T2DM with or at high risk for CVD, incorporating the cardiovascular effects of antihyperglycemic agents.

The educational program Improving Cardiovascular Outcomes in T2DM: Personalizing Antihyperglycemic Therapy will familiarize primary care physicians with the pathophysiology of CVD in T2DM, results of cardiovascular outcomes trials of antihyperglycemics, and recommendations from several societies regarding the use of these agents in patients with T2DM who have or are at risk for CVD.

Jointly provided by the Potomac Center for Medical Education and Rockpointe

Education resources provided in collaboration with Health Union LLC

This activity is supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Merck & Co., Inc. and Novo Nordisk.

Click here for the PCME Privacy Policy